Author name: Stocktok

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

ModernaMRNAannounced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million. The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on expanding and boosting its mRNA-manufacturing capabilities. It expects OriCiro’s proprietary technologies to support its portfolio of mRNA-based therapeutics and vaccines. OriCiro is

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout Read More »

Oil prices steady as investors debate Trump 2.0 policies By Reuters

By Arathy Somasekhar (Reuters) – Oil prices were little changed in early trading on Wednesday as markets weighed U.S. President Donald Trump’s declaration of a national energy emergency on his first day in office and its impact on supply. futures eased 3 cents, to $79.26 per barrel, while U.S. West Texas Intermediate crude futures (WTI)

Oil prices steady as investors debate Trump 2.0 policies By Reuters Read More »

Trump escalates campaign to dismantle government diversity programs By Reuters

By Daniel Trotta (Reuters) -U.S. President Donald Trump escalated his assault on diversity programs on Tuesday by pressuring the private sector to join the initiative, ordering aviation officials to review diversity hires and telling employees of DEI government offices and programs they would be placed on paid leave. The measures come one day after Trump

Trump escalates campaign to dismantle government diversity programs By Reuters Read More »

Should You Retain Willis Towers (WTW) in Your Portfolio?

Willis Towers Watson Public Limited CompanyWTWhas been benefiting from growing healthcare premiums, improved client retention, higher software sales and solid balance sheet. Growth Projections The Zacks Consensus Estimate for 2023 earnings per share is pegged at $15.23, indicating year-over-year increases of 12.6%. The expected long-term earnings growth is pegged at 16%, better than the industry

Should You Retain Willis Towers (WTW) in Your Portfolio? Read More »

Harmony Biosciences chief commercial officer sells shares worth $1.15m By Investing.com

Following these transactions, Dierks no longer holds shares in the company. Harmony (JO:) Biosciences, which maintains an excellent financial health score according to InvestingPro data, holds more cash than debt on its balance sheet and demonstrates strong liquidity with a current ratio of 3.24. The pharmaceutical company continues to focus on developing and commercializing innovative

Harmony Biosciences chief commercial officer sells shares worth $1.15m By Investing.com Read More »

LanzaTech to Form New Joint Venture and Launch Spin-Out of LanzaX Business, and Appoints Interim CFO of LanzaTech By Investing.com

Announces intent to spin out and form a growth-oriented joint venture for LanzaX, the Company’s  differentiated synthetic biology platform, with Tharsis Capital joining as new LanzaX strategic partner to accelerate financing for the synbio development pipeline Appoints new Interim Chief Financial Officer of LanzaTech to streamline biorefining platform growth priorities and heighten focus on cost

LanzaTech to Form New Joint Venture and Launch Spin-Out of LanzaX Business, and Appoints Interim CFO of LanzaTech By Investing.com Read More »